Vistagen Therapeutics Inc (VTGN)

$0.59 -0.01 (-2.33%)
Market Cap 23.24M
Revenue (ttm) 490,000.00
Net Income (ttm) -51.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,493.88%
Debt to Equity Ratio 0.00
Volume 329,800
Avg Vol 779,434
Day's Range N/A - N/A
Shares Out 39.62M
Stochastic %K 42%
Beta 0.33
Analysts Hold
Price Target $0.97

Company Profile

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 577 3600
Address:
343 Allerton Avenue, South San Francisco, United States
sumset1965
sumset1965 Apr. 3 at 8:57 PM
$VTGN I know, I know, holding a bio ticker is almost worse than going to a casino. But once in a while, you end up at tRump's casino and win big. 🥳
0 · Reply
focafoca99
focafoca99 Apr. 3 at 8:44 PM
$VTGN disclosed a Nasdaq audit committee compliance issue after Mary Rotunno's board resignation reduced the committee to two members.
1 · Reply
mb0157
mb0157 Apr. 2 at 8:31 PM
$VTGN 8k just out. Notice last sentence. Company issued notice to nasdaw that they plan on being in compliance by time needed.
1 · Reply
Esterostktrader
Esterostktrader Apr. 2 at 7:06 PM
$IBB $VTGN $XBI just sold an Aug $3 for .25. Crazy risk reward
0 · Reply
Esterostktrader
Esterostktrader Apr. 2 at 6:59 PM
$VTGN someone still buying Aug $5 calls for .20. If you are long this stock selling those is a no brainer! Getting 1/3 of the current share price as a hedge and worst case our shares get called away at 5.20 net price $XBI $IBB
0 · Reply
mb0157
mb0157 Apr. 2 at 6:48 PM
$VTGN possible we see new board member announced after hours today???
0 · Reply
mb0157
mb0157 Apr. 2 at 3:57 PM
$VTGN countdown to ADAA April 9th is now on. More than uoa happening now. Just gotta look and put puzzle together
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Apr. 2 at 3:33 PM
$VTGN more volume than usual
0 · Reply
Esterostktrader
Esterostktrader Apr. 2 at 3:13 PM
$VTGN crazy premium, was selling Aug $1 puts for .75. Break even .25. No brainer
0 · Reply
Esterostktrader
Esterostktrader Apr. 2 at 2:56 PM
$VTGN added at .595 and sold $5 call for .20. Risk/reward stupid to the upside. Break even around .40. Going to sell those all day….
2 · Reply
Latest News on VTGN
Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the Firm Regarding the Upcoming March 16th Lead Plaintiff Deadline

Mar 11, 2026, 4:36 PM EDT - 24 days ago

Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the Firm Regarding the Upcoming March 16th Lead Plaintiff Deadline

Vistagen to Participate in Upcoming Investor Conferences

Mar 3, 2026, 8:30 AM EST - 4 weeks ago

Vistagen to Participate in Upcoming Investor Conferences

Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference

Feb 25, 2026, 8:30 AM EST - 5 weeks ago

Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference

Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

Feb 12, 2026, 4:30 PM EST - 7 weeks ago

Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

Feb 9, 2026, 5:21 PM EST - 7 weeks ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

VTGN Investors Encouraged to Seek Lead Plaintiff Role in Vistagen Therapeutics Securities Class Actoin Case with Johnson Fistel

Feb 6, 2026, 9:52 AM EST - 2 months ago

VTGN Investors Encouraged to Seek Lead Plaintiff Role in Vistagen Therapeutics Securities Class Actoin Case with Johnson Fistel

Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

Feb 4, 2026, 8:30 AM EST - 2 months ago

Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

Jan 29, 2026, 8:24 AM EST - 2 months ago

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

Jan 22, 2026, 10:45 AM EST - 2 months ago

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jan 16, 2026, 5:06 PM EST - 2 months ago

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study

Dec 17, 2025, 12:42 PM EST - 3 months ago

Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Dec 17, 2025, 8:30 AM EST - 3 months ago

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Appoints Nick Tressler as Chief Financial Officer

Dec 1, 2025, 8:30 AM EST - 4 months ago

Vistagen Appoints Nick Tressler as Chief Financial Officer

Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Nov 26, 2025, 8:30 AM EST - 4 months ago

Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

Nov 13, 2025, 4:30 PM EST - 5 months ago

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Nov 10, 2025, 8:30 AM EST - 5 months ago

Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Vistagen to Participate in Stifel Healthcare Conference 2025

Nov 5, 2025, 8:30 AM EST - 5 months ago

Vistagen to Participate in Stifel Healthcare Conference 2025

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Nov 3, 2025, 8:30 AM EST - 5 months ago

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Vistagen Appoints Paul Edick to its Board of Directors

Oct 29, 2025, 8:30 AM EDT - 5 months ago

Vistagen Appoints Paul Edick to its Board of Directors

Vistagen to Present at The Menopause Society 2025 Annual Meeting

Oct 16, 2025, 8:30 AM EDT - 6 months ago

Vistagen to Present at The Menopause Society 2025 Annual Meeting

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 9, 2025, 8:30 AM EDT - 7 months ago

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Aug 7, 2025, 4:30 PM EDT - 8 months ago

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Jul 31, 2025, 8:30 AM EDT - 8 months ago

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Jul 24, 2025, 8:30 AM EDT - 9 months ago

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Jul 15, 2025, 8:30 AM EDT - 9 months ago

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Jun 25, 2025, 8:30 AM EDT - 10 months ago

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Jun 17, 2025, 4:30 PM EDT - 10 months ago

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Jun 12, 2025, 8:30 AM EDT - 10 months ago

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

Jun 2, 2025, 8:30 AM EDT - 10 months ago

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

May 28, 2025, 8:30 AM EDT - 11 months ago

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

May 23, 2025, 8:30 AM EDT - 11 months ago

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Apr 17, 2025, 8:30 AM EDT - 1 year ago

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Mar 19, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Mar 4, 2025, 8:30 AM EST - 1 year ago

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Feb 20, 2025, 8:30 AM EST - 1 year ago

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Feb 13, 2025, 4:30 PM EST - 1 year ago

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Feb 6, 2025, 8:30 AM EST - 1 year ago

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Feb 5, 2025, 8:30 AM EST - 1 year ago

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Jan 14, 2025, 8:30 AM EST - 1 year ago

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Jan 10, 2025, 8:30 AM EST - 1 year ago

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Vistagen to Present at the Stifel 2024 Healthcare Conference

Nov 14, 2024, 8:30 AM EST - 1 year ago

Vistagen to Present at the Stifel 2024 Healthcare Conference

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

Nov 7, 2024, 4:20 PM EST - 1 year ago

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

sumset1965
sumset1965 Apr. 3 at 8:57 PM
$VTGN I know, I know, holding a bio ticker is almost worse than going to a casino. But once in a while, you end up at tRump's casino and win big. 🥳
0 · Reply
focafoca99
focafoca99 Apr. 3 at 8:44 PM
$VTGN disclosed a Nasdaq audit committee compliance issue after Mary Rotunno's board resignation reduced the committee to two members.
1 · Reply
mb0157
mb0157 Apr. 2 at 8:31 PM
$VTGN 8k just out. Notice last sentence. Company issued notice to nasdaw that they plan on being in compliance by time needed.
1 · Reply
Esterostktrader
Esterostktrader Apr. 2 at 7:06 PM
$IBB $VTGN $XBI just sold an Aug $3 for .25. Crazy risk reward
0 · Reply
Esterostktrader
Esterostktrader Apr. 2 at 6:59 PM
$VTGN someone still buying Aug $5 calls for .20. If you are long this stock selling those is a no brainer! Getting 1/3 of the current share price as a hedge and worst case our shares get called away at 5.20 net price $XBI $IBB
0 · Reply
mb0157
mb0157 Apr. 2 at 6:48 PM
$VTGN possible we see new board member announced after hours today???
0 · Reply
mb0157
mb0157 Apr. 2 at 3:57 PM
$VTGN countdown to ADAA April 9th is now on. More than uoa happening now. Just gotta look and put puzzle together
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Apr. 2 at 3:33 PM
$VTGN more volume than usual
0 · Reply
Esterostktrader
Esterostktrader Apr. 2 at 3:13 PM
$VTGN crazy premium, was selling Aug $1 puts for .75. Break even .25. No brainer
0 · Reply
Esterostktrader
Esterostktrader Apr. 2 at 2:56 PM
$VTGN added at .595 and sold $5 call for .20. Risk/reward stupid to the upside. Break even around .40. Going to sell those all day….
2 · Reply
Esterostktrader
Esterostktrader Apr. 2 at 2:38 PM
$VTGN big call sweep! Sell upside calls now, sold some Aug $5 for .20. Lots of premium out there now
0 · Reply
marketCaptain
marketCaptain Apr. 1 at 4:52 PM
$VTGN According to Singh, Company will apply for a one trial NDA in case pal4 is a miss. Using The stable response in The fasedienol arm through all historical trials, combined with the open label results
2 · Reply
skyrockets_Inc
skyrockets_Inc Apr. 1 at 3:07 PM
$VTGN bought more today here with my $CYCN winnings
0 · Reply
MakesHerSquirt
MakesHerSquirt Apr. 1 at 12:25 AM
$VTGN I definitely have seen crazier things happen. GOODLUCK EVERYONE see you on the other side. luck fortunes the
0 · Reply
BioBum
BioBum Mar. 31 at 3:45 PM
$VTGN I’ll never forget where I was during pal 2 release. I was waiting in the lobby to drop my car off at a body shop. I’m sitting on the couches. BANG! The email hits. Stock goes $2 to $6, $6 to $8, $8-$14, $15-$22, $22 to $28, $28 to $36, $36 to $44. All happening in premarket. I hold. I hold like an idiot that I am. I would then go on to lose it all again. Enjoy the ride, guys
6 · Reply
BioBum
BioBum Mar. 30 at 10:46 PM
$VTGN I’m waiting for the palisade 4 trial being successful and it blasts off to $16 lol
3 · Reply
marketCaptain
marketCaptain Mar. 30 at 6:14 PM
$VTGN Why The selloff
1 · Reply
OwlKing
OwlKing Mar. 29 at 6:51 PM
$OCGN $VTGN $PSKY $GNS Loading
0 · Reply
kimgysen
kimgysen Mar. 28 at 10:09 AM
$VTGN We've been screwed over!
2 · Reply
MaskMaker
MaskMaker Mar. 28 at 2:49 AM
$MVIS $NXL $FLNA $VTGN
0 · Reply
marketCaptain
marketCaptain Mar. 27 at 8:35 PM
$VTGN One day closer to The topline readout of pal 4
0 · Reply
TradeWithCreed
TradeWithCreed Mar. 27 at 8:11 PM
$PSKY $VTGN $OCGN $COEP ii
0 · Reply